FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3006233208> ?p ?o ?g. }

• W3006233208 endingPage "572" @default.
• W3006233208 startingPage "560" @default.
• W3006233208 abstract "The anti-CD19 chimeric antigen receptor (CAR)-T cell therapy tisagenlecleucel was evaluated in the global, phase 2 JULIET study in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). We correlated tisagenlecleucel cellular kinetics with clinical/product parameters in 111 patients treated in JULIET. Tisagenlecleucel persistence in responders and nonresponders, respectively, was demonstrated for 554 and 400 days maximum by flow cytometry and for 693 and 374 days maximum by quantitative polymerase chain reaction (qPCR). No relationships were identified between cellular kinetics (qPCR) and product characteristics, intrinsic/extrinsic factors, dose, or immunogenicity. Most patients with 3-month response had detectable transgene at time of response and continued persistence for ≥6 months. Expansion (maximal expansion of transgene/CAR-positive T-cell levels in vivo postinfusion [Cmax]) was potentially associated with response duration but this did not reach statistical significance (hazard ratio for a twofold increase in Cmax, 0.79; 95% confidence interval, 0.61-1.01). Tisagenlecleucel expansion was associated with cytokine-release syndrome (CRS) severity and tocilizumab use; no relationships were observed with neurologic events. Transgene levels were associated with B-cell levels. Dose was associated with CRS severity, but this was not statistically significant after adjusting for baseline tumor burden. In contrast to the results from B-cell precursor acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia, similar exposure was observed in DLBCL in this study regardless of response and expansion was lower in DLBCL than B-ALL, likely from differences in cancer location and/or T-cell intrinsic factors. Relationships between expansion and CRS severity, and lack of relationships between dose and exposure, were similar between DLBCL and B-ALL. Tisagenlecleucel cellular kinetics in adult relapsed/refractory DLBCL improve current understanding of in vivo expansion and its relationships with safety/efficacy endpoints. This trial was registered at www.clinicaltrials.gov as #NCT02445248." @default.
• W3006233208 created "2020-02-24" @default.
• W3006233208 creator A5002963327 @default.
• W3006233208 creator A5011386306 @default.
• W3006233208 creator A5011480006 @default.
• W3006233208 creator A5015361329 @default.
• W3006233208 creator A5016370299 @default.
• W3006233208 creator A5024474361 @default.
• W3006233208 creator A5028164155 @default.
• W3006233208 creator A5028693685 @default.
• W3006233208 creator A5034083208 @default.
• W3006233208 creator A5034222353 @default.
• W3006233208 creator A5034517642 @default.
• W3006233208 creator A5036293139 @default.
• W3006233208 creator A5042828762 @default.
• W3006233208 creator A5048369262 @default.
• W3006233208 creator A5055938005 @default.
• W3006233208 creator A5060311157 @default.
• W3006233208 creator A5064132655 @default.
• W3006233208 creator A5072835425 @default.
• W3006233208 creator A5073146208 @default.
• W3006233208 creator A5080630441 @default.
• W3006233208 creator A5082092102 @default.
• W3006233208 creator A5086354986 @default.
• W3006233208 date "2020-02-11" @default.
• W3006233208 modified "2023-09-30" @default.
• W3006233208 title "Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL" @default.
• W3006233208 cites W2056560462 @default.
• W3006233208 cites W2108669049 @default.
• W3006233208 cites W2118796952 @default.
• W3006233208 cites W2145985838 @default.
• W3006233208 cites W2215470046 @default.
• W3006233208 cites W2342423058 @default.
• W3006233208 cites W2595092734 @default.
• W3006233208 cites W2622031359 @default.
• W3006233208 cites W2623114472 @default.
• W3006233208 cites W2756071038 @default.
• W3006233208 cites W2760653955 @default.
• W3006233208 cites W2773804840 @default.
• W3006233208 cites W2775369717 @default.
• W3006233208 cites W2787301955 @default.
• W3006233208 cites W2792281539 @default.
• W3006233208 cites W2890272132 @default.
• W3006233208 cites W2891294964 @default.
• W3006233208 cites W2891902322 @default.
• W3006233208 cites W2900391822 @default.
• W3006233208 cites W2903062212 @default.
• W3006233208 cites W2907012610 @default.
• W3006233208 cites W2952224846 @default.
• W3006233208 cites W2956358944 @default.
• W3006233208 cites W2985159446 @default.
• W3006233208 doi "https://doi.org/10.1182/bloodadvances.2019000525" @default.
• W3006233208 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7013261" @default.
• W3006233208 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32045475" @default.
• W3006233208 hasPublicationYear "2020" @default.
• W3006233208 type Work @default.
• W3006233208 sameAs 3006233208 @default.
• W3006233208 citedByCount "83" @default.
• W3006233208 countsByYear W30062332082020 @default.
• W3006233208 countsByYear W30062332082021 @default.
• W3006233208 countsByYear W30062332082022 @default.
• W3006233208 countsByYear W30062332082023 @default.
• W3006233208 crossrefType "journal-article" @default.
• W3006233208 hasAuthorship W3006233208A5002963327 @default.
• W3006233208 hasAuthorship W3006233208A5011386306 @default.
• W3006233208 hasAuthorship W3006233208A5011480006 @default.
• W3006233208 hasAuthorship W3006233208A5015361329 @default.
• W3006233208 hasAuthorship W3006233208A5016370299 @default.
• W3006233208 hasAuthorship W3006233208A5024474361 @default.
• W3006233208 hasAuthorship W3006233208A5028164155 @default.
• W3006233208 hasAuthorship W3006233208A5028693685 @default.
• W3006233208 hasAuthorship W3006233208A5034083208 @default.
• W3006233208 hasAuthorship W3006233208A5034222353 @default.
• W3006233208 hasAuthorship W3006233208A5034517642 @default.
• W3006233208 hasAuthorship W3006233208A5036293139 @default.
• W3006233208 hasAuthorship W3006233208A5042828762 @default.
• W3006233208 hasAuthorship W3006233208A5048369262 @default.
• W3006233208 hasAuthorship W3006233208A5055938005 @default.
• W3006233208 hasAuthorship W3006233208A5060311157 @default.
• W3006233208 hasAuthorship W3006233208A5064132655 @default.
• W3006233208 hasAuthorship W3006233208A5072835425 @default.
• W3006233208 hasAuthorship W3006233208A5073146208 @default.
• W3006233208 hasAuthorship W3006233208A5080630441 @default.
• W3006233208 hasAuthorship W3006233208A5082092102 @default.
• W3006233208 hasAuthorship W3006233208A5086354986 @default.
• W3006233208 hasBestOaLocation W30062332081 @default.
• W3006233208 hasConcept C121608353 @default.
• W3006233208 hasConcept C126322002 @default.
• W3006233208 hasConcept C143998085 @default.
• W3006233208 hasConcept C159654299 @default.
• W3006233208 hasConcept C203014093 @default.
• W3006233208 hasConcept C207103383 @default.
• W3006233208 hasConcept C2777178219 @default.
• W3006233208 hasConcept C2777575956 @default.
• W3006233208 hasConcept C2777701055 @default.
• W3006233208 hasConcept C2778957590 @default.
• W3006233208 hasConcept C2780850621 @default.
• W3006233208 hasConcept C2780868878 @default.

• next